<i>CFH</i> and <i>VIPR2</i> as susceptibility loci in choroidal thickness and pachychoroid disease central serous chorioretinopathy.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 29844195.
- Also identified by DOI 10.1073/pnas.1802212115 and PMC identifier 6004488.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Central serous chorioretinopathy (CSC) is a common disease affecting younger people and may lead to vision loss. CSC shares phenotypic overlap with age-related macular degeneration (AMD). As recent studies have revealed a characteristic increase of choroidal thickness in CSC, we conducted a genome-wide association study on choroidal thickness in 3,418 individuals followed by TaqMan assays in 2,692 subjects, and we identified two susceptibility loci: <i>CFH</i> rs800292, an established AMD susceptibility polymorphism, and <i>VIPR2</i> rs3793217 (<i>P</i> = 2.05 × 10<sup>-10</sup> and 6.75 × 10<sup>-8</sup>, respectively). Case-control studies using patients with CSC confirmed associations between both polymorphisms and CSC (<i>P</i> = 5.27 × 10<sup>-5</sup> and 5.14 × 10<sup>-5</sup>, respectively). The <i>CFH</i> rs800292 G allele is reportedly a risk allele for AMD, whereas the A allele conferred risk for thicker choroid and CSC development. This study not only shows that susceptibility genes for CSC could be discovered using choroidal thickness as a defining variable but also, deepens the understanding of differences between CSC and AMD pathophysiology.
Medical subject headings
- Central Serous Chorioretinopathy
- Choroid
- Complement Factor H
- Genetic Predisposition to Disease
- Polymorphism, Single Nucleotide
- Receptors, Vasoactive Intestinal Peptide, Type II